Market Overview

Vetr Upgrade's REGN's On Price Growth Following Positive Guidance


The Vetr crowd upgraded its rating for Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) from 1 star (Strong Sell), issued three days ago, to 3 stars (Hold). Crowd sentiment at the time of the downgrade was edging cautious, with 55 percent of Vetr user ratings bearish.

May has been good to shares in the pharmaceutical company, which is up more than 17 percent over the first 18 days of the month. This is in part due to a successful earnings report, in addition to the company's affirmation on positive guidance for 2017 that promised continued revenue growth.

Learn how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for Regeneron is down at $437.82, which is still above the average analyst target price of $431.90. Less than 2 percent of Vetr users are holding REGN in their watch lists.

Latest Ratings for REGN

May 2020CFRAMaintainsHold
May 2020SVB LeerinkReiteratesOutperform
May 2020Wells FargoUpgradesEqual-WeightOverweight

View More Analyst Ratings for REGN
View the Latest Analyst Ratings


Related Articles (REGN)

View Comments and Join the Discussion!

Posted-In: VetrBiotech Upgrades Health Care Price Target Crowdsourcing Analyst Ratings

Latest Ratings

BRCB of A SecuritiesMaintains44.0
FIVEB of A SecuritiesMaintains120.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at